1. Home
  2. IMMR vs AGEN Comparison

IMMR vs AGEN Comparison

Compare IMMR & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

HOLD

Current Price

$5.60

Market Cap

216.7M

Sector

Technology

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.42

Market Cap

124.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMMR
AGEN
Founded
1993
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
216.7M
124.4M
IPO Year
1999
1999

Fundamental Metrics

Financial Performance
Metric
IMMR
AGEN
Price
$5.60
$3.42
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$13.50
$14.50
AVG Volume (30 Days)
390.4K
499.8K
Earning Date
02-27-2026
03-16-2026
Dividend Yield
5.50%
N/A
EPS Growth
82.69
100.00
EPS
N/A
N/A
Revenue
$35,013,000.00
$42,877,086.00
Revenue This Year
N/A
$61.42
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$8.89
Revenue Growth
N/A
89.95
52 Week Low
$5.25
$1.38
52 Week High
$8.15
$7.34

Technical Indicators

Market Signals
Indicator
IMMR
AGEN
Relative Strength Index (RSI) 37.89 51.04
Support Level N/A $2.91
Resistance Level $7.08 $4.66
Average True Range (ATR) 0.24 0.26
MACD -0.07 -0.03
Stochastic Oscillator 26.94 42.37

Price Performance

Historical Comparison
IMMR
AGEN

About IMMR Immersion Corporation

Immersion Corp is focused on the creation, design, development, and licensing of haptic technologies that allow people to use its sense of touch more fully as it involves engaging with products and experience the digital world. The company's software focuses on applications in mobile devices, wearables, consumer, and gaming devices markets. It generates revenue from royalty and license fees, and development contract and service fees. Geographically, the company generates a majority of its revenue from Japan, followed by Korea, Germany, United States of America and other countries.

About AGEN Agenus Inc.

Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.

Share on Social Networks: